

Highlights of This Issue 1761

REVIEW

- 1763 | **Targeting Axl and Mer Kinases in Cancer**
Anupam Verma, Steven L. Warner, Hariprasad Vankayalapati, David J. Bearss, and Sunil Sharma

THERAPEUTIC DISCOVERY

- 1774 | **Identification of a Natural Compound by Cell-Based Screening That Enhances Interferon Regulatory Factor-1 Activity and Causes Tumor Suppression**
Jinbo Gao, Yujun Wang, Quanhua Xing, Jin Yan, Maheswari Senthil, Yasir Akmal, Claudia M. Kowolik, Julia Kang, David M. Lu, Ming Zhao, Zhixiu Lin, Christopher H.K. Cheng, M.L. Richard Yip, and John H. Yin

- 1784 | **Telomere Targeting with a New G4 Ligand Enhances Radiation-Induced Killing of Human Glioblastoma Cells**
Patrick Merle, Bertrand Evrard, Anne Petitjean, Jean-Marie Lehn, Marie-Paule Teulade-Fichou, Emmanuel Chautard, Anne De Cian, Lionel Guittat, Phong Lan Thao Tran, Jean-Louis Mergny, Pierre Verrelle, and Andrei Tchirkov

- 1796 | **Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single-Agent Activity and Synergize with Cisplatin**
Tracy M. Neher, Diane Bodenmiller, Richard W. Fitch, Shadia I. Jalal, and John J. Turchi

- 1807 | **A Novel Kinase Inhibitor of FADD Phosphorylation Chemosensitizes through the Inhibition of NF- κ B**
Katrina A. Schinske, Shyam Nyati, Amjad P. Khan, Terence M. Williams, Timothy D. Johnson, Brian D. Ross, Ricardo Pérez Tomás, and Alnawaz Rehemtulla

- 1818 | **A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells**
Koppany Visnyei, Hideyuki Onodera, Robert Damoiseaux, Kuniyasu Saigusa, Syuzanna Petrosyan, David De Vries, Denise Ferrari, Jonathan Saxe, Eduard H. Panosyan, Michael Masterman-Smith, Jack Mottahedeh, Kenneth A. Bradley, Jing Huang, Chiara Sabatti, Ichiro Nakano, and Harley I. Kornblum

- 1829 | **Targeting Tumor-Initiating Cancer Cells with dCD133KDEL Shows Impressive Tumor Reductions in a Xenotransplant Model of Human Head and Neck Cancer**
Nate N. Waldron, Dan S. Kaufman, Seunguk Oh, Zintis Inde, Melinda K. Hexum, John R. Ohlfest, and Daniel A. Vallera

- 1839 | **Genomic Profiling in CEPH Cell Lines Distinguishes between the Camptothecins and Indenoisoquinolines**
Venita Gresham Watson, Nicholas E. Hardison, Tyndall Harris, Alison Motsinger-Reif, and Howard L. McLeod

- 1846 | **An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B**
Georg E. Winter, Uwe Rix, Andrej Lissat, Alexey Stukalov, Markus K. Müllner, Keiryn L. Bennett, Jacques Colinge, Sebastian M. Nijman, Stefan Kubicek, Heinrich Kovar, Udo Kontny, and Giulio Superti-Furga

- 1857 | **Prioritizing Candidate Disease miRNAs by Topological Features in the miRNA Target-Dysregulated Network: Case Study of Prostate Cancer**
Juan Xu, Chuan-Xing Li, Jun-Ying Lv, Yong-Sheng Li, Yun Xiao, Ting-Ting Shao, Xiao Huo, Xiang Li, Yan Zou, Qing-Lian Han, Xia Li, Li-Hua Wang, and Huan Ren

PRECLINICAL DEVELOPMENT

- 1867 **NF-κB Is Required for Smac Mimetic-Mediated Sensitization of Glioblastoma Cells for γ-Irradiation-Induced Apoptosis**
Rebecca Berger, Claudia Jennewein, Viola Marschall, Sabine Karl, Silvia Cristofanon, Liane Wagner, Sri HariKrishna Vellanki, Stephanie Hehlgers, Franz Rödel, Klaus-Michael Debatin, Albert C. Ludolph, and Simone Fulda
- 1876 **ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer**
Nicole Campbell, James Greenaway, Jack Henkin, and Jim Petrik
- 1886 **Targeting the Microtubular Network as a New Antimyeloma Strategy**
Rentian Feng, Shirong Li, Caisheng Lu, Carrie Andreas, Donna B. Stolz, Markus Y. Mapara, and Suzanne Lentzsch
- 1897 **The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors**
Giuseppe Floris, Maria Debiec-Rychter, Agnieszka Wozniak, Cristiana Stefan, Emmanuel Normant, Gavino Faa, Kathleen Machiels, Ulla Vanleeuw, Raf Sciot, and Patrick Schöffski
- 1909 **Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma**
Tiffany Khong and Andrew Spencer
- 1918 **Tumor-Specific Targeting of Pancreatic Cancer with Shiga Toxin B-Subunit**
Matthias Maak, Ulrich Nitsche, Larissa Keller, Petra Wolf, Marianne Sarr, Marine Thiebaud, Robert Rosenberg, Rupert Langer, Jörg Kleeff, Helmut Friess, Ludger Johannes, and Klaus-Peter Janssen
- 1929 **CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin**
Naoki Mine, Sayaka Yamamoto, Naoya Saito, Satoshi Yamazaki, Chikako Suda, Machiyo Ishigaki, Donald W. Kufe, Daniel D. Von Hoff, and Takumi Kawabe

- 1939 **Dual-Fluorescence Isogenic High-Content Screening for MUC16/CA125 Selective Agents**
Thapi D. Rao, Nestor Rosales, and David R. Spriggs
- 1949 **Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft**
Joana M. Senra, Brian A. Telfer, Kim E. Cherry, Cian M. McCrudden, David G. Hirst, Mark J. O'Connor, Stephen R. Wedge, and Ian J. Stratford
- 1959 **Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models**
Rachel M. Squillace, David Miller, Michelle Cookson, Scott D. Wardwell, Lauren Moran, David Clapham, Frank Wang, Tim Clackson, and Victor M. Rivera
- 1969 **2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression**
Carmine Stolfi, Roberta Caruso, Eleonora Franzè, Angelamaria Rizzo, Angela Rotondi, Ivan Monteleone, Massimo Claudio Fantini, Francesco Pallone, and Giovanni Monteleone
- 1982 **CYP2S1 and CYP2W1 Mediate 2-(3,4-Dimethoxyphenyl)-5-Fluorobenzothiazole (GW-610, NSC 721648) Sensitivity in Breast and Colorectal Cancer Cells**
Boon Shing Tan, Kai Hung Tiong, Ashwin Muruhadas, Nirmal Randhawa, Heng Lugh Choo, Tracey D. Bradshaw, Malcolm F.G. Stevens, and Chee-Onn Leong

1993

Impact of *KRAS* Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy


Seung Tae Kim, Do Hyoung Lim, Kee-Taek Jang, Taekyu Lim, Jeeyun Lee, Yoon-La Choi, Hye-Lim Jang, Jun Ho Yi, Kyung Kee Baek, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, and Joon Oh Park

BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin

Tamar Safra, Lucia Borgato, Maria Ornella Nicoletto, Linda Rolnitzky, Sharon Pelles-Avraham, Ravit Geva, Martin Edward Donach, John Curtin, Akiva Novetsky, Tal Grenader, Wei-Chu V. Lai, Alberto Gabizon, Leslie Boyd, and Franco Muggia

ABOUT THE COVER

The cover figure depicts a homology model indicating the binding mode of a small molecule inhibitor complex with Axl kinase. The surface represents the active site residues and the spheres depict the hydrophobic and gatekeeper site residue interactions. In addition to the overall conserved structure of the kinase domain, the ATP-binding pockets of Axl and Mer possess features that establish molecular interactions with ATP that are common to other protein kinases. For details, see article by Verma and colleagues on page 1763.



Molecular Cancer Therapeutics

10 (10)

Mol Cancer Ther 2011;10:1761-2007.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/10/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/10/10>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.